Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shamika Gune

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
JAMA Ophthalmology|June 16, 2022
Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical TrialMargaret A Chang, Audrey Kapre, Derrick Kaufman, et al.
Ophthalmology and Therapy|June 27, 2022
Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular DegenerationCharles C Wykoff, Peter A Campochiaro, Dante J Pieramici, et al.
Translational Vision Science & Technology|April 7, 2025
Structural Updates to the Implant and Refill Needle of the Port Delivery PlatformDante J Pieramici, Peter A Campochiaro, Margaret Chang, et al.
Ophthalmology. Retina|November 20, 2020
End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular DegenerationArshad M Khanani, David Callanan, Richard Dreyer, et al.
Ophthalmology. Retina|August 29, 2024
Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular DegenerationPeter A Campochiaro, David Eichenbaum, Margaret A Chang, et al.
Survey of Ophthalmology|February 1, 2019
Microperimetry for geographic atrophy secondary to age-related macular degenerationKarl G Csaky, Praveen J Patel, Yasir J Sepah, et al.
Ophthalmology. Retina|May 19, 2022
Management of Key Ocular Adverse Events in Patients Implanted with the Port Delivery System with RanibizumabCarl C Awh, Giulio Barteselli, Sneha Makadia, et al.
JAMA Ophthalmology|March 6, 2025
Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical TrialArshad M Khanani, Peter A Campochiaro, Jordan M Graff, et al.
American Journal of Ophthalmology|July 15, 2023
Exudation in Patients With Neovascular Age-Related Macular Degeneration Treated With the Port Delivery System or Monthly InjectionsAnam Akhlaq, David Williams, W Lloyd Clark, et al.
Ophthalmology|March 4, 2023
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year ResultsCarl Regillo, Brian Berger, Logan Brooks, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
JAMA Ophthalmology|June 16, 2022
Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical TrialMargaret A Chang, Audrey Kapre, Derrick Kaufman, et al.
Ophthalmology and Therapy|June 27, 2022
Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular DegenerationCharles C Wykoff, Peter A Campochiaro, Dante J Pieramici, et al.
Translational Vision Science & Technology|April 7, 2025
Structural Updates to the Implant and Refill Needle of the Port Delivery PlatformDante J Pieramici, Peter A Campochiaro, Margaret Chang, et al.
Ophthalmology. Retina|November 20, 2020
End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular DegenerationArshad M Khanani, David Callanan, Richard Dreyer, et al.
Ophthalmology. Retina|August 29, 2024
Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular DegenerationPeter A Campochiaro, David Eichenbaum, Margaret A Chang, et al.
Survey of Ophthalmology|February 1, 2019
Microperimetry for geographic atrophy secondary to age-related macular degenerationKarl G Csaky, Praveen J Patel, Yasir J Sepah, et al.
Ophthalmology. Retina|May 19, 2022
Management of Key Ocular Adverse Events in Patients Implanted with the Port Delivery System with RanibizumabCarl C Awh, Giulio Barteselli, Sneha Makadia, et al.
JAMA Ophthalmology|March 6, 2025
Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical TrialArshad M Khanani, Peter A Campochiaro, Jordan M Graff, et al.
American Journal of Ophthalmology|July 15, 2023
Exudation in Patients With Neovascular Age-Related Macular Degeneration Treated With the Port Delivery System or Monthly InjectionsAnam Akhlaq, David Williams, W Lloyd Clark, et al.
Ophthalmology|March 4, 2023
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year ResultsCarl Regillo, Brian Berger, Logan Brooks, et al.
Pageof 4